BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-26 08:30 | English | PDF • 3.0 MB | |||
| 2025-08-26 08:29 |
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical …
|
English | PDF • 82.3 KB | ||
| 2025-08-26 08:29 |
BioInvent gör strategiska portföljförändringar för att accelerera ledande klini…
|
Swedish | PDF • 82.1 KB | ||
| 2025-06-12 09:00 |
BioInvent presenterar lovande fas 2a-monoterapidata för BI-1808 i CTCL på EHA 2…
|
Swedish | PDF • 82.1 KB | ||
| 2025-06-12 09:00 |
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at E…
|
English | PDF • 82.1 KB | ||
| 2025-05-27 14:00 |
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInve…
|
Swedish | PDF • 89.3 KB | ||
| 2025-05-27 14:00 |
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInve…
|
English | PDF • 90.2 KB | ||
| 2025-05-14 15:30 |
BioInvent presenterar ytterligare fas 2a-data för BI-1808 monoterapi i CTCL på …
|
Swedish | PDF • 81.5 KB | ||
| 2025-05-14 15:30 |
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, ri…
|
English | PDF • 81.8 KB | ||
| 2025-05-14 15:30 |
Uppdatering från BioInvents fas 2a-trippelkombinationsstudie med BI-1206, ritux…
|
Swedish | PDF • 81.9 KB | ||
| 2025-05-14 15:30 |
BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA…
|
English | PDF • 80.8 KB | ||
| 2025-04-29 17:01 |
Beslut på BioInvents årsstämma 2025
|
Swedish | PDF • 71.8 KB | ||
| 2025-04-29 17:01 |
Resolutions at BioInvent’s Annual General Meeting 2025
|
English | PDF • 71.6 KB | ||
| 2025-04-29 08:00 | Swedish | PDF • 3.8 MB | |||
| 2025-04-29 08:00 | English | PDF • 3.7 MB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
